|
gptkbp:instanceOf
|
gptkb:drug
thiazide-like diuretic
|
|
gptkbp:ATCCode
|
C03BA11
|
|
gptkbp:bioavailability
|
93%
|
|
gptkbp:brand
|
Lozol
Natrilix
|
|
gptkbp:CASNumber
|
26807-65-8
|
|
gptkbp:contraindication
|
severe liver impairment
severe kidney impairment
|
|
gptkbp:discoveredBy
|
gptkb:Servier_Laboratories
|
|
gptkbp:eliminationHalfLife
|
14-18 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C16H16ClN3O3S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Indapamide
|
|
gptkbp:introducedIn
|
1977
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits sodium reabsorption in distal tubules
|
|
gptkbp:meltingPoint
|
160-162°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
71-79%
|
|
gptkbp:PubChem_CID
|
3700
3572
CHEMBL1531
DB00808
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
fatigue
headache
hypokalemia
|
|
gptkbp:synonym
|
1-(4-chloro-3-sulfamoylbenzamido)-2-methylindoline
|
|
gptkbp:UNII
|
8Y164V895Y
|
|
gptkbp:usedFor
|
edema
hypertension
|
|
gptkbp:bfsParent
|
gptkb:Servier_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
7
|